GenSight Biologics (EPA:SIGHT) said today that the first person was treated in a first-in-man trial evaluating GenSight’s gene therapy candidate, GS030-DP, in combination with a wearable optronic visual stimulation device, GS030-MD.
Scientists are evaluating the drug-device combination in 18 people with retinitis pigmentosa.
Get the full story at our sister site, Drug Delivery Business News.